ClinicalTrials.gg
TerminatedNCT02091063Updated Aug 6, 2024Results posted

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

A Phase 1/2 interventional study of ACY-1215 in Lymphoma and Lymphoid Malignancies, sponsored by Jennifer Amengual. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Jennifer Amengual · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,910 studies in Lymphoma with a site in United States — 161 open to participants now, 288 under way, 15 of them phase 3. Lymphoma · United States.

Enrollment
1,068th of 1,595
23 · median 36
Started
2014
with 59 others
Phase 1/2
218 of 1,910
22 open now
Registered
1,289th of 1,910
by date

Among the 1,910 studies in Lymphoma with a site in United States, this one is the 1,068th largest by enrollment of the 1,595 interventional ones that give a count, is one of 60 that started in 2014, is one of 218 in phase 1/2, and was the 1,289th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

161 of the 1,910 studies in Lymphoma with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,910 studies in Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This will be an open-label, single agent, multi-institutional phase Ib/II study of ACY-1215 for the treatment of patients with relapsed or refractory lymphoid malignancies. The target population will include patients with histologically confirmed relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma, with an expansion cohort of patients with mantle cell lymphoma.

The phase Ib will be conducted to determine the safety and tolerability of two dosing schedules of ACY-1215 monotherapy in patients with lymphoid malignancies. Patients will be accrued simultaneously to two dose cohorts (Arm A and Arm B) of ACY-1215. Selection into each cohort will occur by alternation. All patients will take the prescribed dose of ACY-1215 orally for 28 consecutive days. Patients enrolled into Arm A will take ACY-1215 160 mg daily (QD), whereas patients enrolled into Arm B will take ACY-1215 160 mg twice daily (BID). ACY-1215 will be supplied as a liquid for oral administration (PO). Each dose will be administered at least 1 hour after ingestion of food followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose. Frequency in phase II will be determined based on Phase Ib results.

Read the detailed description

The emergence of epigenetic therapies has identified pan-class deacetylase (DAC) inhibitors as effective therapeutic agents for the treatment of lymphoma. While pan-class DAC inhibitors have led to FDA indications, clinical activity has been limited to the T-cell derived malignancies. The mechanism of action remains largely unknown and off-target effects lead to side effects including fatigue, gastrointestinal disturbances, and cytopenias. Recently, the development of isoform selective DAC inhibitors have opened the opportunity to investigate their mechanism. It is now recognized that DAC inhibitors not only have epigenetic properties, but have direct effects on transcription factors (p53), oncogenes (Bcl6), and protein degradation pathways (aggresome). Proteolysis occurs primarily through the ubiquitin-proteosome pathway. In states where this pathway is physiologically overwhelmed or therapeutically inhibited, the aggresome sequesters proteins for degradation. DAC6 is a class IIb deacetylase that facilitates misfolded protein transport to the aggresome for proteosome-independent proteolysis. Inhibition of the aggresome activates the unfolded protein response (UPR) pathway, a cellular quality control mechanism with two primary functions: (1) to promote survival during cellular endoplasmic reticulum (ER) stress by chaperoning proteins back for re-folding and halting further transcription until homeostasis is restored and (2) to signal CCAAT/enhancer binding protein (C/EBP)-homologous protein (CHOP) mediated apoptosis when homeostasis cannot be reestablished[9]. While most cells depend on both branches of the UPR to coordinate protein folding, lymphocytes physiologically down-regulate the UPR-apoptosis pathway, specifically CHOP, to allow for generation of high affinity antibodies. In addition to initiating genetic abnormalities (translocations and point mutations) lymphomas inherit this biology, and thus gain a survival advantage.

It has been shown ACY-1215, an Histone Deacetylase 6 (HDAC6)-selective, orally active small-molecule enzyme inhibitor has had single agent activity in a panel of lymphoma cell lines and mouse models, and marked synergistic activity with several agents such as bortezomib, carfilzomib, and ibrutinib, unpublished data. ACY-1215 has been studied in vivo in models of multiple myeloma and lymphoma with marked activity both as a single agent and in combination with bortezomib. Therefore ACY-1215 will be investigated for treatment of lymphoma as a single agent leading to future studies evaluating its effects in combination with other targeted agents known to be active in lymphoma and synergistic with ACY-1215.

03

Conditions studied

  • Lymphoma
  • Lymphoid Malignancies

Keywords

  • hematologic malignancies
  • hodgkin
  • hodgkins
  • non-hodgkin
  • non-hodgkins
  • mantle cell lymphoma
  • follicular
  • lymphoma
  • lymphoid malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have confirmed non-Hodgkin's lymphoma or Hodgkin's lymphoma (World Health Organization criteria), for which they are unwilling or unable to undergo an stem cell transplant. Patients may have relapsed after prior stem cell transplant.
  • Must have received chemotherapy. No upper limit to number of prior therapies.
  • Patients must have .
  • Patients must be age ≥ 18.
  • Patient has a Performance Status score of ≥70 or (ECOG) performance status score of ≤2
  • The patient or the patient's legal representative is able to understand the risks of the study and provide signed and authorization to use protected health information (in accordance with national and local privacy regulations).
  • Patient has adequate bone marrow reserve, as evidenced by:

    • (ANC) of ≥1.0x109/L.
    • count of ≥50x109/L.
  • Patient has adequate renal function, as evidenced by a creatinine within the institutional limits of normal or a calculated of ≥30 mL/min according to the Cockcroft-Gault equation.
  • Patient has adequate hepatic function, as evidenced by serum values \<2.0 mg/dL and serum (ALT) and/or aspartate transaminase (AST) values \<3 × the (ULN) of the local laboratory reference range. (Patients with isolated elevations in alkaline phosphatase (ALP) \<5 × ULN in the presence of bony disease are not excluded from participating in the study.)
  • Females of must have a negative urine or serum pregnancy test within 7 days of (C1D1) and have adequate . (A female is considered to be not of childbearing potential if she has undergone bilateral oophorectomy or if she has been menopausal without a menstrual period for 12 consecutive months.)

Exclusion criteria

Exclusion Criteria:

  • Prior Therapy

    1. Patients who have had chemotherapy or radiotherapy within 2 weeks of study drug treatment or those who have not recovered from adverse events due to agents administered
    2. Systemic that have not been stabilized to the equivalent of ≤10 mg/day prednisone during the 7 days prior to the start of the study drugs.
    3. No monoclonal antibody within 3 months unless evidence of disease progression.
  • Patients may not be receiving any other agents.
  • Patients with known central nervous system , including lymphomatous meningitis
  • Any known cardiac abnormalities such as:

    • Congenital long syndrome
    • Corrected QT (QTc) interval ≥ 500 milliseconds;
  • Uncontrolled inter-current illness
  • Pregnant or nursing women
  • Patient is known to be (HIV)-positive
  • Active Hepatitis A, , or infection
  • Patient has a history of surgery that would interfere with the administration or absorption of the oral study drugs
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Phase Ib and II: ACY-1215

    Participants will receive Phase Ib Arm A: ACY-1215 QD or Arm B: ACY-1215 BID. Once Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.

    Drug: ACY-1215

Interventions

  • DrugRicolinostatStudies of RicolinostatRicolinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.

    Also known as: Ricolinostat

06

What researchers measure

Primary outcomes

  1. Number of Patients Who Experience a Dose-limiting Toxicity (DLT)

    This is designed to establish the safety of 2 dose schedules of ACY-1215 in patients with relapsed or refractory lymphoid malignancies treated with ACY-1215. If more than 1/3 or 2/6 patients experience a DLT in Phase I, there will be no expansion.

    Time frame: Up to 1 year

  2. Objective Response Rate

    The anti-tumor activity of ACY-1215 will be measured by the number of subjects with the response rate in Phase II: complete response \[CR\] and partial response \[PR\]. Complete Response (CR) - Disappearance of all non-target lesions by PET/CT. Nodal Mass: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative or (b) Variably FDG-avid or PET negative; regression to normal size on CT. Spleen/Liver: Not palpable, nodules disappeared. Partial Response (PR) - Regression of measurable disease and no new sites. Nodal Mass: 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes, (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen/Liver: 50% decrease in SPD of nodules.

    Time frame: Up to 3 years

07

Results

Posted Aug 6, 2024

Participant flow

Cohort 1: 160 mg Once Daily (Phase 1)
Participant flow — Cohort 1: 160 mg Once Daily (Phase 1)
MilestoneACY-1215: 160 mg Once Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Expansion) (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 2)
Started3000
Completed3000
Not completed0000
Cohort 2: 160 mg Twice Daily (Phase 1)
Participant flow — Cohort 2: 160 mg Twice Daily (Phase 1)
MilestoneACY-1215: 160 mg Once Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Expansion) (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 2)
Started0600
Completed0600
Not completed0000
Expansion: 160 mg Twice Daily (Phase 1)
Participant flow — Expansion: 160 mg Twice Daily (Phase 1)
MilestoneACY-1215: 160 mg Once Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Expansion) (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 2)
Started0040
Completed0040
Not completed0000
160 mg Twice Daily (Phase 2)
Participant flow — 160 mg Twice Daily (Phase 2)
MilestoneACY-1215: 160 mg Once Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 1)ACY-1215: 160 mg Twice Daily (Expansion) (Phase 1)ACY-1215: 160 mg Twice Daily (Phase 2)
Started0008
Completed0008
Not completed0000

Outcome measures

PrimaryNumber of Patients Who Experience a Dose-limiting Toxicity (DLT)

This is designed to establish the safety of 2 dose schedules of ACY-1215 in patients with relapsed or refractory lymphoid malignancies treated with ACY-1215. If more than 1/3 or 2/6 patients experience a DLT in Phase I, there will be no expansion.

Time frame:
Up to 1 year

No measurements were reported for this outcome.

PrimaryObjective Response Rate

The anti-tumor activity of ACY-1215 will be measured by the number of subjects with the response rate in Phase II: complete response \[CR\] and partial response \[PR\]. Complete Response (CR) - Disappearance of all non-target lesions by PET/CT. Nodal Mass: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative or (b) Variably FDG-avid or PET negative; regression to normal size on CT. Spleen/Liver: Not palpable, nodules disappeared. Partial Response (PR) - Regression of measurable disease and no new sites. Nodal Mass: 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes, (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen/Liver: 50% decrease in SPD of nodules.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Participants1/21 (4.8%)0/21 (0%)21/21 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAll Participants
DiarrheaGastrointestinal disorders16/21
NauseaGeneral disorders13/21
FatigueGeneral disorders9/21
PainGeneral disorders9/21
VomitingGeneral disorders8/21
CoughRespiratory, thoracic and mediastinal disorders6/21
Creatinine increasedHepatobiliary disorders5/21
Abdominal painGastrointestinal disorders4/21
ConfusionGeneral disorders4/21
HyperkalemiaBlood and lymphatic system disorders4/21

Baseline characteristics

All baseline characteristics were collected from the study participants agnostic to their Arm assignment. Baseline characteristics were NOT collected per dose level thus cannot be reported per dose level.

Age, Continuous
Age, Continuous(years)All Participants
Median55 (24 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female10
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino4
Not Hispanic or Latino17
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White16
Black or African American4
Asian1
Disease type
Disease type(Participants)All Participants
Hodgkin's Lymphoma7
Diffuse large B-cell Lymphoma (DLBCL)5
T-cell Lymphoma4
Marginal Zone Lymphoma (MZL)2
Mantle Cell Lymphoma (MCL)1
Follicular Lymphoma2
08

Study locations

2 sites
  • Moffit Cancer Center
    Tampa, Florida 33612, United States
  • Columbia University Medical Center
    New York, New York 10019, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Feb 2019, 58 months.

Results were first posted in Aug 2024, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 19, 2014
StartActual
Apr 2, 2014
Primary completionActual
Feb 25, 2019
CompletionActual
May 5, 2019
Results first posted
Aug 6, 2024
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02091063
Lead sponsor
Jennifer Amengual
Responsible party
Jennifer Amengual (Assistant Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Mar 19, 2014
Start date
Apr 2, 2014
Primary completion
Feb 25, 2019
Completion
May 5, 2019
Results posted
Aug 6, 2024
Last update
Aug 6, 2024

Study contacts

Jennifer E Amengual, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ricolinostat

Start the discussion